

Clinical research is becoming much more complicated both in terms of the questions being asked and the complexity of trial designs. Researchers need to be collaborating more widely to address the difficult underlying questions that are emerging, and a ‘one-size-fits-all’ trial design approach is no longer relevant. Many of you are designing ambitious programs which include genomics and translational research. In response to this evolution, we have to develop tools to drive progress and ensure maximum patient benefit from all trials. Despite an urgent need for new medications, clinical trials in Parkinson’s have a relatively low rate of success. Although many reasons have been proposed for this, we need strategies that provide solid evidence for differentiating success.

This panel is intended to discuss clinical trial design considerations, challenges in implementations, and regulatory paths for slowing the progression of PD.

Panelists:

Kun Jin, PhD, FDA

Atul Bhattaram, PhD, FDA

Larry Alphas, MD PhD, Janssen SA

Ravi Anand, MD

---